Magtrace® Lymphatic Tracer
A single-injection dual-tracer, designed to simplify the marking and removal of sentinel lymph nodes.
Overview
Documents
The World’s First Non-Radioactive Dual-Tracer1
Iron oxide. Sugar. Salt. Water. Four simple ingredients that together provide a proven and effective way to stage early breast cancer.
Evidence-based
Multiple clinical trials have shown the Magtrace lymphatic tracer to be non-inferior to the combination of radioisotopes and blue dyes.2
Flexible
Inject weeks prior to surgery or in the operating theatre, without compromising on efficacy or accuracy.3
Safe
No reported cases of anaphylaxis in over 200,000 patients treated with the Magtrace lymphatic tracer.4
Radiation-Free
Remove the burden of a nuclear medicine program, with the ease of use of the Magtrace lymphatic tracer.
Unlock the Advantage of Time
The Breast Health Continuum of Care offers integrated solutions for clinical confidence, workflow efficiency and compassionate patient care. It gives more women, more time in better health.
The Magtrace Lymphatic Tracer is part of the Hologic Breast Surgery Solution.
Clinical Evidence
The Magtrace lymphatic tracer has been featured in countless clinical publications demonstrating its accuracy in detecting sentinel lymph nodes.5
14,000+
patients in Magtrace lymphatic tracer clinical publications.5
1.96
average nodes retrieved per patient.6
98.2%
sentinel lymph node detection rate per patient.7
Sentimag® System: One platform enabling multiple procedures
Our most advanced surgical guidance system yet. All you need within one platform to mark and localise lesions and lymph nodes. No wires. No radioactivity. No brainer.
Visit Our Virtual Hospital
Browse our portfolio of Breast Health solutions in 3D. See how you can unlock the advantage of time across the entire Breast Continuum of Care.
Insights
MedTech Innovation News (2018) Breast cancer device receives FDA approval. https://www.cambridgenetwork.co.uk/news/breast-cancer-device-receives-fda-approval. Accessed March 2, 2026.
Pantiora et al (2022) Evolution and refinement of magnetically guided sentinel lymph node detection in breast cancer: meta-analysis. Br J Surg. 2023 Mar 30;110(4):410-419. doi: 10.1093/bjs/znac426 (Featuring 20 comparative studies for the Magseed® marker and guidewires)
Data on file at Endomag. Device Classification for CE Marking Magtrace (2025) SIE-002, V9.0. Endomag (Magtrace® Lymphatic Tracer Instructions for Use). MTR-006US Iss 7.0, March 2025
Complaints data on file at Endomag. Data correct as of March 2026.
Data on file at Endomag. Internal Meta-Analysis 270525 of Clinical Studies - Data correct as of March 2026
Data on file at Endomag. Scientific and Clinical Literature Review – Magtrace – November 2025 (P415J003). Data correct as of March 2026.
Karakatsanis et al (2023) Delayed Sentinel Lymph Node Dissection in Patients with a Preoperative Diagnosis of Ductal Cancer In Situ by Preoperative Injection with Superparamagnetic Iron Oxide (SPIO) Nanoparticles: The SentiNot Study. Ann Surg Oncol. 2023 Jul;30(7):4064-4072. doi: 10.1245/s10434-022-13064-0 (Study featuring 254 patients from 6 hospitals)
2797
Emergo Europe BV, Westervoortsedijk 60, 6827 AT Arnhem, The Netherlands.
Notified Body number wherever applicable
EC Representative Information wherever applicable